Beneficial actions of statins in the reduction of atrial fibrillation and stabilization and regression of coronary plaques: But how and why?

Circulation Journal

Volumn 75, Issue 1, 2011, Pages 224-225

  Das, Undurti N ^a,b  

^a UND LIFE SCIENCES   (United States)

^b JAWAHARLAL NEHRU TECHNOLOGICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; ESSENTIAL FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOXIN; MYELOPEROXIDASE; POLYUNSATURATED FATTY ACID;

CORONARY ARTERY ATHEROSCLEROSIS; DISEASE CONTROL; DRUG MECHANISM; DRUG POTENTIATION; FATTY ACID METABOLISM; HEART ATRIUM FIBRILLATION; HUMAN; LETTER; NONHUMAN;

ATRIAL FIBRILLATION; CORONARY ARTERY BYPASS, OFF-PUMP; CORONARY ARTERY DISEASE; FATTY ACIDS, ESSENTIAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPID METABOLISM; PREOPERATIVE CARE; TREATMENT OUTCOME;

EID: 78651251322     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0939     Document Type: Letter

References (25)

1. Kinoshita T, Asai T, Nishimura O, Hiramatsu N, Suzuki T, Kambara A, et al. Statin for prevention of atrial fibrillation after off-pump coronary artery bypass grafting in Japanese patients. Circ J 2010; 74: 1846-1851.
2. Kodama K, Komatsu S, Ueda Y, Takayama T, Yajima J, Nanto S, et al. Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound: The TOGETHAR Trial. Circ J 2010; 74: 1922-1928.
3. Das UN. Essential fatty acids-a review. Current Pharmaceutical Biotech 2006; 7: 467-482.
4. Das UN. Essential fatty acids: Biochemistry, physiology, and pathology. Biotechnology J 2006; 1: 420-439.
5. Nakamura N, Hamazaki T, Jokaji H, Minami S, Kobayashi M. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentration in patients with hyperlipidemia. Int J Clin Lab Res 1998; 28: 192-195.
6. Duncan RE, El-Sohemy A, Archer MC. Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin. Cancer Lett 2005; 224: 221-228.
7. Das UN. Essential fatty acids as possible mediators of the actions of statins. Prostaglandins Leukot Essen Fatty Acids 2001; 65: 37-40.
8. Nordoy A, Bonaa KH, Sandset PM, Hansen JB, Nilsen H. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol 2000; 20: 259-265.
9. Nordoy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis 2001; 11: 7-16.
10. Birnbaum Y, Ye Y, Lin Y, Freeberg SY, Nishi SP, Martinez JD, et al. Augmentation of myocardial production of 15-epi-lipoxin A4 by pioglitazone and atorvastatin in the rat. Circulation 2006; 114: 929-935.
11. Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16: 470-474.
12. London B, Albert C, Anderson ME, Giles WR, Van Wagoner DR, Balk E, et al. Omega-3 fatty acids and cardiac arrhythmias: Prior studies and recommendations for future research: A report from the National Heart, Lung, and Blood Institute and Office Of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007; 116: e320-e335.
13. Macchia A, Monte S, Pellegrini F, Romero M, Ferrante D, Doval H, et al. Omega-3 fatty acid supplementation reduces one-year risk of atrial fibrillation in patients hospitalized with myocardial infarction. Eur J Clin Pharmacol 2008; 64: 627-634.
14. Patel D, Shaheen M, Venkatraman P, Armaganijan L, Sanchez JE, Horton RP, et al. Omega-3 polyunsaturated fatty acid supplementation reduced atrial fibrillation recurrence after pulmonary vein antrum isolation. Indian Pacing Electrophysiol J 2009; 9: 292-298.
15. Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP. Serum longchain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation 2009; 120: 1315-1321.
16. Serhan CN, Yacoubian S, Yang R. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol 2008; 3: 279-312.
17. Baker N, O'Meara SJ, Scannell M, Maderna P, Godson C. Lipoxin A4: Anti-inflammatory and anti-angiogenic impact on endothelial cells. J Immunol 2009; 182: 3819-3826.
18. Wu SH, Lu C, Dong L, Zhou GP, He ZG, Chen ZQ. Lipoxin A4 inhibits TNF-alpha-induced production of interleukins and proliferation of rat mesangial cells. Kidney Int 2005; 8: 35-46.
19. Ariel A, Chiang N, Arita M, Petasis NA, Serhan CN. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-α secretion from human T cells. J Immunol 2003; 170: 6266-6272.
20. Annenberg G, Moussignac RL, Gronert K, Devchand PR, Schmidt BA, Guilford WJ, et al. Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 2004; 143: 43-52.
21. Krishnamoorthy S, Recchiuti A, Chiang N, Yacoubian S, Lee CH, Yang R, et al. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 2010; 107: 1660-1665.
22. Weinberger B, Quizon C, Vetrano AM, Archer F, Laskin JD, Laskin DL. Mechanisms mediating reduced responsiveness of neonatal neutrophils to lipoxin A4. Pediatr Res 2008; 64: 393-398.
23. Das UN. Lipoxins A4 may function as an endogenous anti-arrhythmic molecule. Med Hypotheses 2010 (in press).
24. Davidenkova EF, Shafron MG. Myeloperoxidase of neutrophils and its possible role in lipid peroxidation processes in arteriosclerosis. Klin Med (Mosk) 1989; 67: 56-58.
25. Malle E, Marsche G, Panzenboeck U, Sattler W. Myeloperoxidasemediated oxidation of high-density lipoproteins: Fingerprints of newly recognized potential proatherogenic lipoproteins. Arch Biochem Biophys 2006; 445: 245-255.